Answers to multiple choice questions of survey section 1 for Campania region
| Questions | Multiple-choice responses | All, n (%) | CC, n (%) | UH, n (%) | GH, n (%) |
| N=38 | N=10 | N=12 | N=16 | ||
| 1. How do you triage your (CP-ICI) patients for SARS-CoV-2? | ☐ By telephone the day before the appointment | 7 (18.4) | 1 (10) | 2 (16.7) | 4 (25) |
| ☐ Outside the hospital the same day of the clinic appointment | 6 (15.8) | 4 (40) | 0 (0) | 2 (12.5) | |
| ☐ By telephone the day before the appointment and outside the clinic the day of the appointment | 25 (65.8) | 5 (50) | 10 (83.3) | 10 (62.5) | |
| 2. Who among CP-ICI patients do you preferentially use telemedicine? | ☐ Patients in follow-up after finishing ICI adjuvant treatment | 2 (5.3) | 0 (0) | 0 (0) | 2 (12.5) |
| ☐ Patients in follow-up who achieve complete response | 1 (2.6) | 0 (0) | 0 (0) | 1 (6.3) | |
| ☐ Both | 30 (78.9) | 8 (80) | 12 (100) | 10 (62.5) | |
| ☐ None of the above, I am not using telemedicine | 5 (13.2) | 2 (20) | 0 (0) | 3 (18.8) | |
| 3. How do you manage the new patients with cancer who need to start ICIs for metastatic disease? | ☐ Delay ICI start for COVID-19 in all patients | 0 (0) | 0 | 0 | 0 |
| ☐ Triage screening for COVID-19 risk factors | 34 (89.5) | 8 (80) | 12 (100) | 14 (87.5) | |
| ☐ Both | 2 (5.3) | 1 (10) | 0 (0) | 1 (6.3) | |
| ☐ None of the above | 2 (5.3) | 1 (10) | 0 (0) | 1 (6.3) | |
| 4. How do you manage the new patients with cancer who need to start ICIs for adjuvant purpose? | ☐ Delay ICI start for COVID-19 in all patients | 1 (2.6) | 1 (10) | 0 (0) | 0 (0) |
| ☐ Triage screening for COVID-19 risk factors | 29 (76.3) | 8 (80) | 8 (66.7) | 13 (81.3) | |
| ☐ Both | 5 (13.2) | 1 (10) | 4 (33.3) | 0 (0) | |
| ☐ None of the above | 3 (7.9) | 0 (0) | 0 (0) | 3 (18.8) | |
| 5. Do you have any CP-ICI who tested positive to SARS-CoV-2? | ☐ Yes | 12 (31.6) | 5 (50) | 6 (50) | 1 (6.3) |
| ☐ No | 26 (68.4) | 5 (50) | 6 (50) | 15 (93.8) | |
| 6. If yes, how many? | ☐<10 | 12 (100) | 5 (100) | 6 (100) | 1 (100) |
| ☐ 10–20 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| ☐ 20–50 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| ☐ 50–100 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| 7. If yes, the most frequent CP-ICI SARS-CoV-2 positive are affected by? | ☐ Uro-genital cancers | 3 (25) | 1 (20) | 0 (0) | 0 (0) |
| ☐ Thoracic cancers | 5 (41.7) | 0 (0) | 6 (100) | 1 (100) | |
| ☐ Melanoma | 4 (33.3) | 4 (80) | 0 (0) | 0 (0) | |
| ☐ Head and neck cancers | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| ☐ Other | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| 8. How do you manage CP-ICI showing suspicious symptoms for COVID-19? (more than 1 option allowed) | 1. Order the SARS-CoV-2 test and continue with the ICIs avoiding delays | 2 (5.3) | 2 (20) | 0 (0) | 0 (0) |
| 2. Suspend the ICIs while waiting for the test results | 15 (39.5) | 6 (60) | 5 (41.7) | 4 (25) | |
| 3. Ask for Rx thorax even in the absence of severe respiratory symptoms | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| 4. Ask for thorax CT scan even in the absence of severe respiratory symptoms | 1 (2.6) | 0 (0) | 0 (0) | 1 (6.3) | |
| 5. Ask for blood test including: CBC, lactate dehydrogenase, high-sensitivity C reactive protein, interleukin-6, D-dimer | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| 6. 2+5 | 2 (5.3) | 0 (0) | 0 (0) | 2 (12.5) | |
| 7. 2+3 | 2 (5.3) | 0 (0) | 0 (0) | 2 (12.5) | |
| 8. 2+3+5 | 4 (10.5) | 0 (0) | 4 (33.3) | 0 (0) | |
| 9. 2+3+4 | 1 (2.6) | 0 (0) | 0 (0) | 1 (6.3) | |
| 10. 2+4 | 4 (10.5) | 1 (10) | 2 (16.7) | 1 (6.3) | |
| 11. 2+4+5 | 7 (18.4) | 1 (10) | 1 (8.3) | 5 (31.3) |
CBC, complete blood count; CC, cancer center; CP, cancer patient; CP-ICI, cancer patients undergoing or candidate for immune checkpoint inhibitor; GH, general hospital; ICI, immune checkpoint inhibitor; N, number; UH, university hospital.